Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 30, Issue 3, 2007, Pages 234-238

  Chiappino, Isabella ^a,c   Destefanis, Paolo ^b   Addeo, Alfredo ^a   Galetto, Alessandra ^a   Cucchiarale, Giuseppina ^b   Munoz, Fernando ^c   Zitella, Andrea ^b   Ferrando, Ugo ^b   Fontana, Dario ^b   Ricardi, Umberto ^c   Tizzani, Alessandro ^b   Bertetto, Oscar ^a  

^a Centro OncoEmatologicoSubalpino   (Italy)

^b Centro di Riferimento Per la Ricerca Diagnosi e Cura del Tumore Prostatico   (Italy)

^c MOLINETTE HOSPITAL   (Italy)

Author keywords

Hormone refractory prostate cancer; Paclitaxel; Phase II study; Weekly

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; ESTRAMUSTINE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; RANITIDINE; RECOMBINANT ERYTHROPOIETIN;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE PAIN; CANCER SURVIVAL; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPEPSIA; DYSPNEA; EMBOLISM; ERYTHROCYTE TRANSFUSION; FATIGUE; FEBRILE NEUTROPENIA; HEART ATRIUM FIBRILLATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEARTBURN; HEMATURIA; HUMAN; HYPOKALEMIA; LYMPHEDEMA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PROSTATE CANCER; RECTUM HEMORRHAGE; SENSORY NEUROPATHY; SIDE EFFECT; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME; URINE RETENTION; WEIGHT GAIN; WEIGHT REDUCTION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 34249992004     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000256706.16313.49     Document Type: Article

References (20)

1. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
2. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
3. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
4. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
5. Milross CG, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst. 1996;88:1308-1314.
6. Milas L, Hunter NR, Kurdoglu B, et al. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with Taxol. Cancer Chemother Pharmacol. 1995;35:297-303.
7. Lopes NM, Adams EG, Pitts TW, et al. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol. 1993;32:235-242.
8. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusion in the treatment of metastatic breast cancer. J Clin Oncol. 1998;16:3353-3361.
9. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996;2:1843-1849.
10. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res. 2000;60:1878-1886.
11. Perez EA, Vogel CL, Irwin DH, et al. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer J Clin Oncol. 2001;19:4216-4223.
12. Markman M, Hall J, Spitz D, et al. Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol. 2002;20:2365-2369.
13. Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol. 1998;16:153-158.
14. Vaughn DJ, Broome C, Hussain M, et al. A phase II trial of weekly paclitaxel in previously treated advanced urothelial cancer. J Clin Oncol. 2002;20:937-940.
15. Trivedi C, Redman B, Flaherty LE, et al. Weekly 1-hour infusion of paclitaxel: clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer. 2000;89:431-436.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
17. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
18. Hanfelt JJ, Slack RS, Gehan EA. A modification of Simon's optimal design for phase II trials when the criterion is median sample size. Control Clin Trials. 1999;20:555-566.
19. Berry WR, Hathorn JW, Dakhil SR, et al. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer. 2004;3:104-111.
20. Vaughn DJ, Brown AW, Harker WG, et al. Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma. Cancer. 2004;100:746-750.